Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study.

@article{Yang2012EfficacyAS,
  title={Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study.},
  author={Lin Yang and Lei Shi and Qiang Fu and Huihua Xiong and Mengxian Zhang and Shiying Yu},
  journal={Oncology letters},
  year={2012},
  volume={3 4},
  pages={935-939}
}
Sorafenib has been confirmed as an effective drug in advanced renal cell carcinoma (RCC). This study aimed to evaluate the long-term efficacy and safety of sorafenib in ethnic Chinese patients with advanced RCC, and to develop optimal treatment strategies for Asian patients. Between May 2006 and August 2011, 30 patients with advanced RCC were treated with sorafenib in the Oncology Center, Tongji Hospital. All 30 patients received continuous treatment with 400 mg of sorafenib orally twice daily… CONTINUE READING
Highly Cited
This paper has 28 citations. REVIEW CITATIONS